Peripheral and cranial nerve sheath tumors

Current Opinion in Neurology

Volumn 18, Issue 5, 2005, Pages 604-610

  Mrugala, Maciej M ^a   Batchelor, Tracy T ^a   Plotkin, Scott R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Neurofibromatosis; Peripheral nerve sheath tumor; Schwannoma; Schwannomatosis

Indexed keywords

AMITRIPTYLINE; DOCOSAHEXAENOIC ACID; EPIDERMAL GROWTH FACTOR; FLUORODEOXYGLUCOSE; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; OPIATE; OXCARBAZEPINE; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; PREDNISONE; PROTEIN P53; TOPIRAMATE; VASCULOTROPIN INHIBITOR;

ACOUSTIC NEURINOMA; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CRANIAL NERVE TUMOR; DRUG DOSE REGIMEN; DRUG MEGADOSE; ELECTROMYOGRAPHY; HEARING LOSS; HUMAN; MALIGNANT TRANSFORMATION; MULTIPLE ISOLATED NEUROFIBROMA; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PERIPHERAL NERVE TUMOR; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; REVIEW; SCHWANNOMATOSIS; SIGNAL TRANSDUCTION; SPINAL CORD COMPRESSION; SPINAL NEUROFIBROMA; STEREOTAXIC SURGERY; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 26944497220     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000179507.51647.02     Document Type: Review

References (38)

1. Gutmann DH, Aylsworth A, Carey JC, et al. JAMA 1997; 278:51-57.
2. Rosenberg SI. Natural history of acoustic neuromas. Laryngoscope 2000; 110:497-508.
3. Ramsden RT, Moffat DA. Intracanalicular acoustic neuromas; the case for early surgery. Clin Otolaryngol 1994; 19:1-2.
4. O'Reilly BF, Murray CD, Hadley DM. The conservative management of acoustic neuroma; review of forty four patients with magnetic resonance imaging. Clin Otolaryngol 2000; 25:93-97.
5. Kishore A, O'Reilly BF. A clinical study of vestibular schwannomas in type 2 neurofibromatosis. Clin Otolaryngol 2000; 25:561-565.
6. O'Reilly BF, Mehanna H, et al. Growth rate of non-vestibular intracranial schwannomas. Clin Otolaryngol 2004; 29:94-97.
7. Smouha EE, Yoo M, Mohr K, et al. Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. Laryngoscope 2005; 115:450-454. This important paper consolidates our current understanding and approach to treatment of vestibular schwannomas.
8. Stroper IS, Classock ME, Jackson CG, et al. Management of non-acoustic intra-cranial nerve neuromata. Am J Otol 1998; 19:484-490.
9. Shahinian HK, Eby JB, Ocon M. Fully endoscopic excision of vestibular schwannomas. Minim Invas Neurosurg 2004; 47:329-332.
10. Kartush JM, Lundy LB. Facial nerve outcome in acoustic neuroma surgery. Otolaryngol Clin North Am 1992; 25:623-647.
11. Low WK. Enhancing hearing preservation in endoscopic-assisted excision of acoustic neuroma via retrosigmoid approach. J Laryngol Otol 1999; 113:973-977.
12. Flickinger JC, Kondziolka D, Niranjan A, Lunsford LD. Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods. J Neurosurg 2001; 94:1-6.
13. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med 1998; 339:1426-1433.
14. Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 2005; 102 (Suppl):195-199. The authors describe their experience with radiosurgery in a large group of patients with vestibular schwannomas proving the method to be effective and safe.
15. Ishihara H, Saito K, Nishizaki T, et al. CyberKnife radiosurgery for vestibular schwannoma. Minim Invas Neurosurg 2004; 47:290-293.
16. Viola A, Major T, Mangel L, et al. Brachytherapy of vestibular schwannomas: report of three cases. Minim Invas Neurosurg 2004; 47:382-385. This presents a novel approach to treatment in a selected group of patients.
17. Caye-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurootol 2005; 26:98-101.
18. Gouveris H, Mewes T, Maurer J, Mann W. Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery. J Otorhinolaryngol Relat Spec 2005; 67:30-33.
19. MacCollin M, Woodfin W, Kron D, Short MP. Schwannomatosis: a clinical and pathologic study. Neurology 1996; 46:1072-1079.
20. Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000; 54:71-76.
21. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64:1838-1845. Paper important for clinical practice. Authors describe diagnostic criteria for Schwannomatosis and differentiate this entity from neurofibromatoses.
22. Huang JH, Simon SL, Nagpal S, et al. Management of patients with Schwannomatosis: Report of six cases and review of literature. Surg Neurol 2004; 62:353-361.
23. Blakley P, Louis DN, Short PM, MacCollin M. A clinical study of patients with multiple isolated neurofibromas. J Med Genet 2001; 38:485-488.
24. Korf BR, Henson JW, Stemmer-Rachamomov. Case records of the Massachusetts General Hospital. Case 13-2005. A 48-year-old man with weakness of the limbs and multiple tumors of spinal nerves. N Engl J Med 2005; 352:1800-1808.
25. Kluwe L, Tatagiba M, Funsterer C, Mautner VF. NF1 mutations and clinical spectrum in patients with spinal neurofibromas. J Med Genet 2003; 40:368-371.
26. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006-2021.
27. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39:311-314.
28. Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor. The clinical spectrum and outcome of treatment. Neurology 2003; 61:696-698.
29. Kim DH, Murovic JA, Tiel RL, et al. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 2005; 102:246-255.
30. Cashen DV, Parisien RC, Raskin K, et al. Survival data for patients with malignant schwannoma Clin Orthop Relat Res 2004; 426:69-73.
31. Bhattacharya AK, Perrin R, Guha A. Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol 2004; 69:335-349. This is an excellent review of the pathology and management of PNTs with a useful paradigm describing a strategy for patients with MPNSTs.
32. Kourea HP, Orlow I, Scheithauer BW, et al. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 1999; 155:1860-1866.
33. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 1990; 87:5435-5439.
34. Badache A, DeVreis GH. Neurofibrosarcoma-derived Schwann cells over-express platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol 1998; 177:334-342.
35. Li H, Velasco-Miguel S, Vass WC, et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the NF1:p53 mouse tumor model. Cancer Res 2002; 62:4507-4513.
36. Mashour GA, Drissel SN, Frahm S, et al. Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids. Oncogene 2005; 24:2367-2374.
37. Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type I neurofibromatosis. Am J Med Genet 1999; 89:23-30.
38. Angelov L, Guha A. Peripheral nerve tumors. In: Bernstein M, Berger MS, editors. Neuro-oncology. The essentials. New York: Thieme Medical Publishers Inc; 2000. pp. 434-444.